Rebus (RBSH) 10-K 14 May 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	May 01, 2020	Jun. 30, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Inspyr Therapeutics, Inc.
Entity Central Index Key	0001421204
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Public Float			$ 645,000
Entity Common Stock, Shares Outstanding		150,000,000
Entity File Number	000-55331
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash	$ 4	$ 4
Restricted cash	19	327
Total current assets	23	331
Office and lab equipment, net of accumulated depreciation of $7 and $5		2
Intangible assets, net of accumulated amortization of $229 and $179		33
Total assets	23	366
Current liabilities:
Accounts payable	2,269	2,085
Accrued expenses	1,866	1,814
Convertible debentures, net of unamortized discount of $0 and $281	2,826	2,600
Derivative liability	1,785	2,134
Total current liabilities	8,746	8,633
Total liabilities	8,746	8,633
Commitments and contingencies (Note 8)
Stockholders' deficit:
Convertible preferred stock
Common stock, par value $.0001 per share; 150,000,000 shares authorized, 18,648,753 and 3,383,285 shares issued and outstanding, respectively	2	1
Additional paid-in capital	51,955	51,478
Accumulated deficit	(60,680)	(59,746)
Total stockholders' deficit	(8,723)	(8,267)
Total liabilities and stockholders' deficit	23	366
Series A Convertible preferred stock
Stockholders' deficit:
Convertible preferred stock
Series B Convertible preferred stock
Stockholders' deficit:
Convertible preferred stock
Series C Convertible preferred stock
Stockholders' deficit:
Convertible preferred stock
Series D Convertible preferred stock
Stockholders' deficit:
Convertible preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Office and lab equipment, accumulated depreciation	$ 7	$ 5
Intangible assets, accumulated amortization	229	179
Net of unamortized discount, convertible debentures	$ 0	$ 281
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	29,991,846	29,991,846
Convertible preferred stock, shares issued
Convertible preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	18,648,753	3,383,285
Common stock, shares outstanding	18,648,753	3,383,285
Series A Convertible preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	1,854	1,854
Convertible preferred stock, shares issued	134	134
Convertible preferred stock, shares outstanding	134	134
Series B Convertible preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, shares issued	71	71
Convertible preferred stock, shares outstanding	71	71
Series C Convertible preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	300	300
Convertible preferred stock, shares issued	290	290
Convertible preferred stock, shares outstanding	290	290
Series D Convertible preferred stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	5,000	5,000
Convertible preferred stock, shares issued	5,000
Convertible preferred stock, shares outstanding	5,000

Consolidated Statements of Loss

Consolidated Statements of Losses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 44	$ 208
General and administrative	565	516
Total operating expenses	609	724
Loss from operations	(609)	(724)
Other income (expense):
Gain (loss) on change in fair value of derivative liability	327	1,052
Gain on conversion of debt	125	210
Interest (expense), net	(777)	(550)
Loss before provision for income taxes	(934)	(12)
Provision for income taxes
Net loss	(934)	(12)
Deemed dividend	(54)	(196)
Net loss attributable to common shareholders	$ (988)	$ (208)
Net loss per common share, basic and diluted	$ (0.14)	$ (0.22)
Weighted average shares outstanding, basic and diluted	7,030,340	929,708

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - USD ($) $ in Thousands	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning at Dec. 31, 2017			$ 50,886	$ (59,734)	$ (8,848)
Balance at beginning (in shares) at Dec. 31, 2017	495	436,285
Stock-based compensation			90		90
Conversion of notes		$ 1	502		503
Conversion of notes (in shares)		2,947,000
Net loss				(12)	(12)
Balance at ending at Dec. 31, 2018		$ 1	51,478	(59,746)	(8,267)
Balance at ending (in shares) at Dec. 31, 2018	495	3,383,285
Sale of preferred stock			5		5
Sale of preferred stock, shares	5,000
Conversion of notes		$ 1	472		473
Conversion of notes (in shares)		15,265,468
Net loss				(934)	(934)
Balance at ending at Dec. 31, 2019		$ 2	$ 51,955	$ (60,680)	$ (8,723)
Balance at ending (in shares) at Dec. 31, 2019	5,495	18,648,753

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (934)	$ (12)
operating activities:
Depreciation and amortization	36	19
Stock-based compensation		90
(Gain) loss on change in fair value of derivative liability	(327)	(1,052)
Gain on conversion of debt	(125)	(210)
Amortization of debt discount	281	486
Amortization of finance cost	494	64
Decrease in operating assets:
Prepaid expenses and other assets		4
Increase in operating liabilities:
Accounts payable and accrued expenses	262	407
Cash used in operating activities	(313)	(204)
Cash flows from investing activities:
Cash provided by investing activities
Cash flows from financing activities:
Proceeds from convertible notes		525
Proceeds from sale of preferred stock	5
Cash provided by financing activities	5	525
Net (decrease) increase in cash and restricted cash	(308)	321
Cash and restricted cash, beginning of year	331	10
Cash and restricted cash, end of year	$ 23	$ 331

Background

Background	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND	NOTE 1 – BACKGROUND Inspyr Therapeutics, Inc. ("we", "us", "our company", "our", "Inspyr" or the "Company") was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through our acquisition of Lewis and Clark Pharmaceuticals, Inc., we currently are focusing on a pipeline of small molecule adenosine receptor modulators. The adenosine receptor modulators include A 2B antagonists, dual A 2A /A 2B antagonists, and A 2A agonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor agonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn's disease, psoriasis) as well as improve wound healing and decrease pain. During February 2018, due to a lack of capital, we curtailed substantially all our business operations. In the event that we are able to raise sufficient capital, our major focus would be to: (i) further characterization, in conjunction with Ridgeway Therapeutics, of anti-cancer activity of the current pipeline of A 2B 2A 2B 2A 2B 2A 2B 2A Our ability to execute our business plan is dependent on the amount and timing of cash, if any, that we are able to raise. During February of 2018, we curtailed our operations due to our lack of cash. We are currently using funds raised to maintain our SEC reporting requirements, pay outstanding invoices to our independent registered accounting firm, and other outstanding obligations, the payment of which we believe to be vital to our future operations. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and continue, to the best of our ability, our public company reporting requirements.

Management's Plans to Continue

Management's Plans to Continue as a Going Concern	12 Months Ended
	Dec. 31, 2019
Management Plans to Continue as Going Concern [Abstract]
MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	NOTE 2 – MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our consolidated financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses since inception and have an accumulated deficit of $61 million as of December 31, 2019. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions. To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and cash equivalents and restricted cash balances at December 31, 2019 were approximately $23,000, representing 100% of our total assets. We curtailed substantially all operations in February 2018. Based on our current expected level of operating expenditures, and including approximately $250,000, we raised in March 2020, pursuant to the sale of our senior convertible debentures, we expect to be able to fund our operations into the third quarter of 2020. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, licensing agreements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow us to continue our operations, or if available, on terms favorable or acceptable to us. In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our auditors' report issued in connection with our December 31, 2019 consolidated financial statements expressed an opinion that our capital resources as of the date of their audit report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past the third quarter of 2020. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

Summary of Critical Accounting

Summary of Critical Accounting Policies and Use of Estimates	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Reverse Stock Split On September 17, 2019, the Company's Board of Directors approved a one-for-twenty five (1-for-25) reverse stock split of the Company's common stock ("Reverse Stock Split"). In furtherance of the Reverse Stock Split, the Company has filed an amended and restated certificate of incorporation with the Secretary of State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. Eastern Time on September 30, 2019 ("Effective Time"). Accordingly, at the Effective Time, each of the Company's common stock shareholders received one new share of common stock for every twenty-five shares such shareholder held immediately prior to the Effective Time. The Reverse Stock Split will also affect the Company's outstanding stock options, warrants and other exercisable or convertible instruments and will result in the shares underlying such instruments being reduced and the exercise/conversion price being increased proportionately to the Reverse Stock Split ratio. All share and per share data has been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the September 30, 2019 amendment. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $0.04 million and $0.2 million for the years ended December 31, 2019 and 2018, respectively. Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2019 or 2018. Restricted Cash Restricted cash consists of funds held in trust for the Company. The use of these funds is restricted to: (i) the payment of professional fees in connection with bringing the Company's filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company's securities, such as transfer agent fees and fees payable to the OTCQB and FINRA. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and restricted cash was $0.02 million and $0.3 million at December 31, 2019 and 2018, respectively. As of December 31, 2019 and 2018, there was no cash over the federally insured limit. Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years. Office and Lab Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its equipment for impairment. Depreciation expense was approximately $2,000 and $2,000 for the years ended December 31, 2019 and 2018, respectively. Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2019 and 2018, as they would be anti-dilutive: Year Ended December 31, 2019 2018 Shares underlying options outstanding 7,686 12,941 Shares underlying warrants outstanding 96,330 100,517 Shares underlying convertible notes outstanding 641,119,669 33,133,513 Shares underlying convertible preferred stock outstanding 7,911,825 1,055,825 649,135,510 34,302,796 Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company's balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations. Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible notes with a variable conversion feature. The Company uses the Black-Scholes option-pricing model to value its derivative liability which incorporate the Company's stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes with a variable conversion feature as of December 31, 2019. The tables below summarize the fair values of our financial liabilities as of December 31, 2019 (in thousands): Fair Value at Fair Value Measurement Using 2019 Level 1 Level 2 Level 3 Derivative liability $ 1,785 $ — $ — $ 1,785 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Year ended December 31, 2019 2018 Balance at beginning of year $ 2,134 $ 2,934 Additions to derivative instruments 243 604 Reclassification on conversion (265 ) (352 ) Loss (gain) on change in fair value of derivative liability (327 ) (1,052 ) Balance at end of year $ 1,785 $ 2,134 Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. Stock-Based Compensation We account for our stock-based compensation under ASC 718 "Compensation – Stock Compensation" using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. Through December 31, 2018 we used the fair value method for equity instruments granted to non-employees and used the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. On January 1, 2019, the Company adopted ASU 2018-07, which substantially aligns stock-based compensation for employees and non-employees and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718. The Company used the modified prospective method of adoption. There was no cumulative effect of the adoption of ASC 718. Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2019 that are of significance or potential significance to the Company. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU No. 2017-04"). ASU No. 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. A public business entity that is a SEC filer should adopt the amendments of ASU No. 2017-04 for its annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, " Simplifying the Accounting for Income Taxes

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands). Year Ended December 31, 2019 2018 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 473 $ 503 Debentures converted to common stock 331 361 Derivative liability extinguished upon conversion of notes payable 265 352 Derivative liability issued 243 604 Accounts payable paid through issuance of debentures — 15 There was no cash paid for interest and income taxes for the years ended December 31, 2019 and 2018.

Intellectual Property

Intellectual Property	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTELLECTUAL PROPERTY	NOTE 5 – INTELLECTUAL PROPERTY We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders. Amortization expense recorded during the years ended December 31, 2019 and 2018 was approximately $33,000 and $17,000 for the years ended December 31, 2019 and 2018, respectively. Intangibles have been fully amortized at December 31, 2019.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): December 31, 2019 2018 Accrued compensation and benefits $ 1,326 $ 1,326 Accrued research and development 233 188 Accrued other 307 300 Total accrued expenses $ 1,866 $ 1,814

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITY	NOTE 7 – DERIVATIVE LIABILITY We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. We have issued convertible debentures which contain a variable conversion feature, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the financial statements, with the change in fair value during the periods presented recorded in the statement of operations. During the years ended December 31, 2019 and 2018, we recorded gains of approximately $0.3 million and $1.1 million, respectively, related to the change in fair value of the derivative liabilities during the periods. For purpose of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuations of the derivatives at December 31, 2019 are as follows: 2019 Volatility 238% - 264 % Expected term (years) 3 - 11 months Risk-free interest rate 1.55% – 1.6 % Dividend yield None As of December 31, 2019 and 2018, the derivative liability recognized in the financial statements was approximately $1.8 million and $2.1 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Operating Leases Inspyr currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis. There was no rent expense for the years ended December 31, 2019 and 2018, respectively. Legal Matters The Company is subject at times to legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

Capital Stock and Stockholders'

Capital Stock and Stockholders' Deficit	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
CAPITAL STOCK AND STOCKHOLDERS' DEFICIT	NOTE 9 – CAPITAL STOCK AND STOCKHOLDERS’ EQUITY Preferred Stock As of December 31, 2019, there were outstanding 133.8 shares of Series A Preferred Stock, 71 shares of Series B Preferred Stock, 290.4 shares of Series C Preferred Stock and 5,000 shares of Series D Preferred Stock. During December 2018, we designated 5,000 shares of preferred stock as Series D 0% Convertible Preferred Stock (the “Series D Preferred Stock”). Each share of Preferred Stock has a par value of $0.0001 per share and a stated value equal to $1.00 (the “Stated Value”). With respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2019, only, each share of Series D Preferred Stock held by a Holder, as such, was entitled to 30,001 votes. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series D Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series D Preferred Stock shall vote together with the holders of Common Stock as a single class. Each share of Series D Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Series D Preferred Stock by the Conversion Price. As of December 31, 2019, the Conversion Price is $0.125 per share of Series D Preferred Stock. In December 2015, we issued 1,853 shares of our Series A 0% Convertible Preferred Stock (the “Series A Preferred Stock”), with a stated value of $1,000 per share and the common shares are issuable pursuant to conversion of the Series A Preferred Stock at a conversion price of $112.50 per share as of December 31, 2019, subject to a 9.99% beneficial ownership limitation and subject to adjustment pursuant to stock splits and dividends. The Series A Preferred Stock was subject to adjustment pursuant to anti-dilution protection for subsequent equity sales for a period of 18 months from the effective date of the registration statement registering the shares underlying the Series A Preferred Stock, or until July 29, 2017. In December 2016, we issued 1,000 shares of our Series B 0% Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 per share and the common shares are issuable pursuant to conversion of the Series B Preferred Stock at a conversion price of $18.75 per share as of December 31, 2019, subject to beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales and other conversion price adjustments. In March and April 2017, issued 290.43148 shares of Series C 0% Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock has a stated value of $1,000 and the common shares issuable pursuant to conversion of the Series C Preferred Stock at a conversion price of $18.75 per share as of December 31, 2019, subject to certain beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends, and pursuant to anti-dilution protection for subsequent equity sales for a period of twelve (12) months from the issuance of the Series C Preferred Stock. During January 2019, we issued the 5,000 shares of Series D Convertible Preferred Stock for proceeds of $5,000. As a result past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $13.25 per share at December 31, 2019, (ii) our Series B Preferred Stock has been reduced to $0.01 per share at December 31, 2019, (iii) 200 shares of our Series C preferred stock has been reduced to $0.50 per share at December 31, 2019, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $0.25 per share at December 31, 2019, and (v) our Series D Preferred stock has been reduced to $0.125 per share at December 31, 2019. Equity Financings March 2017 Offering In March, 2017, we sold $200,000 of the Company’s securities consisting of 200 shares of Series C Preferred Stock and an aggregate of 32,001 common stock purchase warrants as described below. The Series C Preferred Stock has a stated value of $1,000 and as of December 31, 2019, is convertible into 400,000 shares of the Company’s common stock, subject to certain beneficial ownership limitations, at a conversion price equal to $0.50 per share for 200 shares of Series C Preferred stock and $0.25 per share for 90.43418 shares of Series C Preferred stock, subject to adjustment. The Conversion Price is subject to adjustment pursuant to stock splits and dividends. The Series C Preferred Stock has anti-dilution protection until the twelve (12) month anniversary of the issuance of the Series C Preferred Stock. The Investors also received an aggregate of approximately: (i) 10,667 Series M common stock purchase warrants (“Series M Warrants”), (ii) 10,667 Series N common stock purchase warrants (“Series N Warrants”) and (iii) 10,667 Series O common stock purchase warrants (“Series O Warrants”) (collectively, the “Warrants”). The Series M Warrants have an exercise price of $0.50 per share (as of December 31, 2019), subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants had an exercise price of $18.75 per share upon issuance, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants had an exercise price of $18.75 upon issuance, subject to adjustment, and a term of twelve (12) months from the date of issuance. The Series N and Series O Warrants have both expired. The Warrants are immediately exercisable and separately transferable from the Series C Preferred Stock. In the event that the shares underlying the Warrants are not subject to a registration statement at the time of exercise, the Warrants may be exercised on a cashless basis after 6 months from the issuance date. The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the Warrants contain anti-dilution protection until the twelve (12) month anniversary of the issuance date. April 2017 Offering In April 2017, we sold $90,431 of the Company’s securities consisting of 90.43148 shares of Series Preferred Stock and an aggregate of 14,469 common stock purchase warrants as described below. The Series C Preferred Stock has a stated value of $1,000 and as of December 31, 2019, is convertible into approximately 361,737 shares of the Company’s common stock, subject to certain beneficial ownership limitations, at a conversion price equal to $0.25, subject to adjustment. The Conversion Price is subject to adjustment pursuant to stock splits and dividends. The Series C Preferred Stock has anti-dilution protection until the twelve (12) month anniversary of the issuance of the Series C Preferred Stock. The Investors also received an aggregate of approximately: (i) 4,823 Series M Warrants, (ii) 4,823 Series N Warrants and (iii) 4,823 Series O Warrants. The Series M Warrants have an exercise price of $0.25 per share (as of December 31, 2019), subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants had an exercise price of $18.75 per share upon issuance, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants had an exercise price of $18.75, upon issuance subject to adjustment, and a term of twelve (12) months from the date of issuance. The Series N and Series O Warrants have both expired. The Warrants are immediately exercisable and separately transferable from the Series C Preferred Stock. In the event that the shares underlying the Warrants are not subject to a registration statement at the time of exercise, the Warrants may be exercised on a cashless basis after 6 months from the issuance date. The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the Warrants contain anti-dilution protection until the twelve (12) month anniversary of the issuance date. Conversion and exercise price resets As a result past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $13.25 per share at December 31, 2019, (ii) 200 shares of our Series C preferred stock has been reduced to $0.50 per share at December 31, 2019, (iii) 90.43418 shares of our Series C Preferred Stock has been reduced to $0.25 per share at December 31, 2019, (iv) our Series D Preferred stock has been reduced to $0.125 per share at December 31, 2019, and (v) our Series B Preferred Stock has been reduced to $0.01 per share at December 31, 2019. The exercise prices of the outstanding warrants issued in conjunction with (i) the Series B Preferred Stock have been reduced to $0.01 per share, (ii) 200 shares of Series C Preferred Stock have been reduced to $0.50 per share, and (iii) 91.43418 shares of Series C preferred Stock have been reduced to $0.25 per share, respectively, as of December 31, 2019. As a result of the reductions of the conversion prices of our preferred stock and warrants, we have recorded deemed dividends of approximately $54,000 and $196,000 during the years ended December 31, 2019 and 2018, respectively. Common Stock On September 17, 2019, the Company’s Board of Directors approved a one-for-twenty five (1-for-25) reverse stock split of the Company’s common stock (“Reverse Stock Split”). In furtherance of the Reverse Stock Split, the Company has filed an amended and restated certificate of incorporation with the Secretary of State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. Eastern Time on September 30, 2019 (“Effective Time”). Accordingly, at the Effective Time, each of the Company’s common stock shareholders will receive one new share of common stock for every twenty five shares such shareholder held immediately prior to the Effective Time. The Reverse Stock Split will also affect the Company’s outstanding stock options, warrants and other exercisable or convertible instruments and will result in the shares underlying such instruments being reduced and the exercise price being increased proportionately to the Reverse Stock Split ratio. All share and per share data has been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the September 30, 2019 amendment. During the year ended December 31, 2019, we issued a total of 15,265,468 shares of common stock, valued at $471,583, upon the conversion of $331,415 principal amount of our convertible debentures During the year ended December 31, 2018, we issued a total of 2,947,000 shares of common stock, valued at $503,308, upon the conversion of $361,255 principal amount of our convertible debentures.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 10 – STOCK OPTIONS Deferred Compensation Plan In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded "top hat" plan which is maintained primarily to provide deferred compensation benefits for a select group of our "management or highly compensated employees" within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards. Inspyr's Compensation Plans The Company's 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provide for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of Inspyr and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans are administered by a committee of non-employee directors (the Committee). The Committee determines: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award. Our 2007 Plan is administered by our board or any of its committees. The purposes of the 2007 Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of our business. The issuance of awards under our 2007 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2007 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock based awards. Our 2007 Plan authorizes the issuance of up to 2,000 shares of common stock for the foregoing awards per fiscal year with an aggregate of 8,000 shares of common stock available for issuance under the 2007 Plan. As of December 31, 2019, we have granted awards under the 2007 Plan equal to approximately 7,228 shares of our common stock, and 5,595 shares have been cancelled or forfeited. Accordingly, there are 6,367 shares of common stock available for future awards under the 2007 Plan. In the event of a change in control, awards under the 2007 Plan will become fully vested unless such awards are assumed or substituted by the successor corporation. Our 2009 Plan, as amended is administered by our Board or any of its committees. The purpose of our 2009 Plan is to advance the interests of the Company and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. The issuance of awards under our 2009 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2009 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock-based awards. As of December 31, 2019, our 2009 Plan authorizes the issuance of up to 8,000 shares of our common stock for the foregoing awards, and we have granted awards under the plan equal to approximately 6,595 common shares, and 4,631 shares have been cancelled or forfeited. Accordingly, there are 6,036 shares of common stock available for future awards under the 2009 Plan. Our Inducement Plan is administered by our board or our compensation committee. The Plan is intended to be used in connection with the recruiting and inducement of senior management and employees. The issuance of wards under the Inducement Plan is at the discretion of the administrator which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. The Company did not seek approval of the Plan by our stockholders. Pursuant to the Inducement Plan, the Company may grant stock options for up to a total of 12,000 shares of common stock to new employees of the Company. As of December 31, 2019, 8,454 grants have been made pursuant to the Plan. Our 2017 Plan is administered by our Board or any of its committees. The purpose of our 2017 Plan is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors and consultants, and to promote the success of the Company's business. The issuance of awards under our 2017 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2017 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock-based awards. As of December 31, 2019, our 2017 Plan authorizes the issuance of up to 80,000 shares of our common stock for the foregoing awards, and we have not granted any awards under the plan. Accordingly, there are 80,000 shares of common stock available for future awards under the 2017 Plan. The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the following line items in the accompanying consolidated statement of losses (in thousands): Years Ended December 31, 2019 2018 Research and development $ — $ 62 General and administrative — 28 Total stock-based compensation expense $ — $ 90 During the year ended December 31, 2018, we accelerated the vesting of all unvested employee options. As of December 31, 2019, there was no unrecognized compensation cost related to non-vested stock options. The following table summarizes stock option activity for the years ended December 31, 2019 and 2018: Number of Weighted- Weighted- Aggregate (in thousands) Outstanding at December 31, 2017 14,252 $ 186.25 Granted — $ — Forfeited (1,311 ) $ 474.75 Outstanding at December 31, 2018 12,941 $ 157.00 3.8 $ — Granted — $ — Forfeited (5,255 ) $ 226.90 Outstanding at December 31, 2019 7,686 $ 109.37 2.9 $ — Exercisable at December 31, 2019 7,686 $ 109.37 2.9 $ — No options were issued or exercised during the years ended December 31, 2019 and 2018.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2019
Warrants [Abstract]
WARRANTS	NOTE 11 – WARRANTS Transactions involving our warrants are summarized as follows: Number of Weighted- Weighted- Aggregate (in thousands) Outstanding at December 31, 2017 121,829 $ 134.75 Granted — $ — Forfeited (21,312 ) $ 396.75 Outstanding at December 31, 2018 100,517 $ 79.00 2.7 $ - Granted — $ — Forfeited (4,187 ) $ 904.91 Outstanding at December 31, 2019 96,330 $ 42.95 1.8 $ - Exercisable at December 31, 2019 96,330 $ 42.95 1.8 $ - No warrants were issued or exercised during the years ended December 31, 2019 and 2018. As a result of recent equity financings and conversions of debentures, the exercise prices of the warrants issued in conjunction with our Series B preferred stock have been reduced to $0.01 and the warrants issued in conjunction with our Series C preferred stock have also been reduced to $0.25 - $0.50 at December 31, 2019. The following table summarizes outstanding common stock purchase warrants as of December 31, 2019: Number of Weighted- Expiration Issued to consultants 3,758 $ 69.57 January 2020 through August 2023 Issued pursuant to 2015 financings 18,415 $ 210.00 July 2020 through December 2020 Issued pursuant to 2016 financings 58,667 $ 0.01 December 2021 Issued pursuant to 2017 financings 15,490 $ 0.42 March 2022 through April 2022 96,330

Convertible Debentures and note

Convertible Debentures and notes	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE DEBENTURES AND NOTES	NOTE 12 – CONVERTIBLE DEBENTURES AND NOTES Effective September 30 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our December 2018 note offering, July 2018 debenture offering and September 2017 debenture offering (collectively, the "Debenture Offerings") and extended the maturity date of such debentures until March 31, 2020 in exchange for the issuance of $96,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in October 2019. The debentures mature on October 1, 2020. These maturity dates of these instruments were extended until July 16, 2020 (see Note 14 – Subsequent Events). Sabby Volatility Warrant Master Fund, Ltd. has paid certain of our accounts payable in the amount of $26,235. We issued $26,235 in new debentures with substantially the same terms as those issued in our Debenture Offerings. The debentures were issued in November 2019. The debentures mature November 20, 2020. On July 16, 2019, we entered into securities purchase agreements ("Securities Purchase Agreement") with certain institutional investors (the "Investors"). Pursuant to the Securities Purchase Agreement, we issued an aggregate of $154,000 of senior convertible debentures ("Debentures") in exchange for the extension of the maturity date of our December 2018 convertible notes and certain of our July 2018 and September 2017 convertible debentures, and the waiver of certain default provisions of our July 2018 and September 2017 convertible debentures. We have charged $154,000 to finance cost at the date of issuance. The Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. Furthermore, without the approval of the Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also required under the Securities Purchase Agreement to hold a shareholder meeting by January 3, 2019 in order to increase the number of authorized shares of Common Stock of the Company such that there are sufficient shares of Common Stock available for issuance underlying the Debentures upon their conversion in full. The Company is also obligated under the Securities Purchase Agreement to pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures. The Investors were additionally given a right of participation in future offerings for a period of up to eighteen (18) months from the date on which the shares underlying the Debentures are registered. The Securities Purchase Agreement also prohibits us from issuing any common stock, subject to certain exemptions, for a period of 60 days following the closing of the Offering, without the written approval of the Investors owning at least 50.1% of the securities issued in the Offering. Additionally, until the twelve month anniversary of the registration of the shares underlying the Debentures, we are prohibited from entering into any agreement to effect any issuance of common stock in a variable rate transaction. On December 13, 2018 we issued an aggregate of $25,000 in convertible promissory notes ("Notes") for cash proceeds of $25,000. The Notes will mature on the earlier of (i) June 30, 2019 or (ii) such time as we raise capital in exchange for the sale of securities ("Maturity Date") and bear interest at 10% per year, payable on the Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to 75% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder. The maturity date of the debentures has been extended to July 16, 2020 (see Note 14). On July 3, 2018, we entered into securities purchase agreements ("Securities Purchase Agreement") with certain institutional investors (the "Investors"). Pursuant to the Securities Purchase Agreement, we sold an aggregate of $515,000 of senior convertible debentures ("Debentures") consisting of $500,000 in cash and the cancellation of $15,000 of obligations of the Company (the "Offering"). Pursuant to the terms of the Securities Purchase Agreement, we will issue $515,000 in principal amount of Debentures. The Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. The maturity date of the debentures has been extended to July 16, 2020 (see Note 14). Furthermore, without the approval of the Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also required under the Securities Purchase Agreement to hold a shareholder meeting by January 3, 2019 in order to increase the number of authorized shares of Common Stock of the Company such that there are sufficient shares of Common Stock available for issuance underlying the Debentures upon their conversion in full. The Company is also obligated under the Securities Purchase Agreement to pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures. The Investors were additionally given a right of participation in future offerings for a period of up to eighteen (18) months from the date on which the shares underlying the Debentures are registered. The Securities Purchase Agreement also prohibits us from issuing any common stock, subject to certain exemptions, for a period of 60 days following the closing of the Offering, without the written approval of the Investors owning at least 50.1% of the securities issued in the Offering. Additionally, until the twelve month anniversary of the registration of the shares underlying the Debentures, we are prohibited from entering into any agreement to effect any issuance of common stock in a variable rate transaction. On September 12, 2017 we entered into an exchange agreement ("Exchange Agreement") with certain holders (the "Investors") of our Series A 0% Convertible Preferred Stock ("Series A Shares") and Series B 0% Convertible Preferred Stock ("Series B Shares"). Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $2.5 million in principal amount of senior convertible debentures ("Debentures") in exchange for 1,614.8125 Series A Shares with a stated value of approximately $1.6 million and 890 Series B Shares with a stated value of approximately $0.9 million. On September 12, 2017, we sold an aggregate of $320,000 of our Debentures. The sale consisted of $250,000 in cash and the cancellation of $70,000 of obligations of the Company. The Debentures to be issued to the Investors (i) are non-interest bearing, (ii) have a maturity date of September 12, 2018 and (iii) are convertible into shares of common stock ("Common Stock") of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The maturity date of the debentures has been extended to July 16, 2020 (see Note 14). The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. Furthermore, without the approval of the Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available. This requirement has been waived by the Investors through July 16, 2020 (see Note 14). In connection with the Offering, the Investors also entered in a registration rights agreement ("Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission ("the Commission") within 45 days from the date of the Registration Rights Agreement to register the resale of 100% of the shares of Common Stock underlying the Debentures and to maintain the effectiveness thereunder. The Company also agreed to have the registration statement declared effective within 75 days from the date of the Registration Rights Agreement and keep the registration statement continuously effective until the earlier of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act of 1933, as amended. We are also obligated to pay the Investors, as partial liquidated damages, a fee of 1.5% of each Investor's subscription amount per month in cash upon the occurrence of certain events, including our failure to file and / or have the registration statement declared effective within the time periods provided. This requirement has been waived by the Investors through July 16, 2020 (see Note 14). The Investors were additionally given a right of participation in future offerings for a period of up to eighteen months from the date in which the shares underlying the Debentures are registered as contemplated in the Registration Rights Agreement. The Securities Purchase Agreement also prohibits the Company from issuing any Common Stock, subject to certain exemptions, for a period of 60 days following the closing of the Offering, without the written approval of the Investors owning at least 50.1% of the securities issued in the Offering. Additionally, until the twelve (12) month anniversary of such effectiveness of the registration statement as contemplated in the Registration Rights Agreement, the Company is prohibited from entering into any agreement to effect any issuance of Common Stock in a variable rate transaction.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 — INCOME TAXES The Company had, subject to limitation, $41.2 million of net operating loss carryforwards at December 31, 2019, of which $39.9 million will expire at various dates through 2037. In addition, the Company has research and development tax credits of approximately $458,000 at December 31, 2019 available to offset future taxable income, which will expire from 2028 through 2037. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance increased by approximately $241,000 and $178,000 for the years ended December 31, 2019 and 2018, respectively. Significant components of deferred tax assets and liabilities are as follows (in thousands): 2019 2018 Deferred tax assets: Net operating loss carryover $ 8,838 $ 8,597 Stock-based compensation 1,920 1,920 Accrued compensation 334 334 Other 30 30 Tax credits 458 458 Total deferred tax assets 11,580 11,339 Less: valuation allowance (11,580 ) (11,339 ) Net deferred tax assets $ — $ — The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2019 and 2018 (computed by applying the U.S. Federal Corporate tax rate of 21% to income before taxes) are as follows: 2019 2018 Statutory federal income tax rate (21.0 )% (21.0 )% State income taxes, net of federal benefits (7.0 )% (7.0 )% Non-deductible items 2.2 % (1,418.0 )% Valuation allowance 25.8 % 1,446.0 % Effective income tax rate — % — % The Company's tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The extent of the public-health impact of the outbreak is currently unknown and rapidly evolving, and the related health crisis could adversely affect the global economy, resulting in an economic downturn. Any disruption of the Company's facilities or those of our suppliers could likely adversely impact the Company's operations. At this time, there is significant uncertainty relating to the potential effect of the novel coronavirus on our business. Between January 1, 2020 and March 31, 2020, the Company issued an aggregate of 131,351,247 shares of common stock upon the conversion of $451,662 principal amount of debentures. On March 6, 2020, the Company sold an aggregate of $250,000 of senior convertible debentures ("Debentures") for cash to existing accredited institutional investors of the Company (the "Offering"). The Debentures issued (i) are non-interest bearing, (ii) have a maturity date of July 16, 2020 and (iii) are convertible into shares of common stock ("Common Stock") of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the holder upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. Furthermore, without the approval of the Debenture holders holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. Effective March 6, 2020, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our December 2018 note offering, July 2018 debenture offering and September 2017 debenture offering (collectively, the "Debenture Offerings") and extended the maturity date of such debentures until July 16, 2020. On May 2, 2020, we sold 5,000 shares of Series E 0% Convertible Preferred Stock to an accredited investor at a price per share of $1.00 for aggregate gross proceeds of $5,000. Each share of Series E Preferred Stock has stated value of $1.00. The Series E Preferred Stock is convertible, at any time after the Original Issue Date at the option of the Holder into that number of shares of Common Stock (Subject to the limitations set forth in Section 6(d) of the certificate of designation of the Series E Preferred Stock), determined by dividing the stated value by the then in effect conversion price. As of the date of issuance, the conversion price is $0.01 per share. With respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, each share of Series E Preferred Stock held by a holder, as such, is entitled to 100,000 votes. On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series E Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series E Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Series E Preferred Stock shall vote together with the holders of Common Stock as a single class.

Summary of Critical Accountin_2

Summary of Critical Accounting Policies and Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Reverse Stock Split	Reverse Stock Split On September 17, 2019, the Company's Board of Directors approved a one-for-twenty five (1-for-25) reverse stock split of the Company's common stock ("Reverse Stock Split"). In furtherance of the Reverse Stock Split, the Company has filed an amended and restated certificate of incorporation with the Secretary of State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. Eastern Time on September 30, 2019 ("Effective Time"). Accordingly, at the Effective Time, each of the Company's common stock shareholders received one new share of common stock for every twenty-five shares such shareholder held immediately prior to the Effective Time. The Reverse Stock Split will also affect the Company's outstanding stock options, warrants and other exercisable or convertible instruments and will result in the shares underlying such instruments being reduced and the exercise/conversion price being increased proportionately to the Reverse Stock Split ratio. All share and per share data has been retroactively restated in the accompanying consolidated financial statements and footnotes for all periods presented to reflect the effects of the September 30, 2019 amendment.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $0.04 million and $0.2 million for the years ended December 31, 2019 and 2018, respectively.
Cash Equivalents	Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2019 or 2018.
Restricted Cash	Restricted Cash Restricted cash consists of funds held in trust for the Company. The use of these funds is restricted to: (i) the payment of professional fees in connection with bringing the Company's filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company's securities, such as transfer agent fees and fees payable to the OTCQB and FINRA.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and restricted cash was $0.02 million and $0.3 million at December 31, 2019 and 2018, respectively. As of December 31, 2019 and 2018, there was no cash over the federally insured limit.
Intangible Assets	Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.
Office and Lab Equipment	Office and Lab Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its equipment for impairment. Depreciation expense was approximately $2,000 and $2,000 for the years ended December 31, 2019 and 2018, respectively.
Loss per Share	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2019 and 2018, as they would be anti-dilutive: Year Ended December 31, 2019 2018 Shares underlying options outstanding 7,686 12,941 Shares underlying warrants outstanding 96,330 100,517 Shares underlying convertible notes outstanding 641,119,669 33,133,513 Shares underlying convertible preferred stock outstanding 7,911,825 1,055,825 649,135,510 34,302,796
Derivative Liability	Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company's balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible notes with a variable conversion feature. The Company uses the Black-Scholes option-pricing model to value its derivative liability which incorporate the Company's stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Fair Value Measurements	Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes with a variable conversion feature as of December 31, 2019. The tables below summarize the fair values of our financial liabilities as of December 31, 2019 (in thousands): Fair Value at Fair Value Measurement Using 2019 Level 1 Level 2 Level 3 Derivative liability $ 1,785 $ — $ — $ 1,785 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Year ended December 31, 2019 2018 Balance at beginning of year $ 2,134 $ 2,934 Additions to derivative instruments 243 604 Reclassification on conversion (265 ) (352 ) Loss (gain) on change in fair value of derivative liability (327 ) (1,052 ) Balance at end of year $ 1,785 $ 2,134
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.
Stock-Based Compensation	Stock-Based Compensation We account for our stock-based compensation under ASC 718 "Compensation – Stock Compensation" using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the shorter of the service period or the vesting period of the stock-based compensation. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. The Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option pricing model. Determining the fair value of stock-based compensation at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based compensation represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. Through December 31, 2018 we used the fair value method for equity instruments granted to non-employees and used the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. On January 1, 2019, the Company adopted ASU 2018-07, which substantially aligns stock-based compensation for employees and non-employees and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718. The Company used the modified prospective method of adoption. There was no cumulative effect of the adoption of ASC 718.
Recent Accounting Pronouncements	Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2019 that are of significance or potential significance to the Company. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of this standard did not have any impact on the Company's consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU No. 2017-04"). ASU No. 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. A public business entity that is a SEC filer should adopt the amendments of ASU No. 2017-04 for its annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, " Simplifying the Accounting for Income Taxes

Summary of Critical Accountin_3

Summary of Critical Accounting Policies and Use of Estimates (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of weighted average shares outstanding	Year Ended December 31, 2019 2018 Shares underlying options outstanding 7,686 12,941 Shares underlying warrants outstanding 96,330 100,517 Shares underlying convertible notes outstanding 641,119,669 33,133,513 Shares underlying convertible preferred stock outstanding 7,911,825 1,055,825 649,135,510 34,302,796
Schedule of fair values of financial liabilities	Fair Value at Fair Value Measurement Using 2019 Level 1 Level 2 Level 3 Derivative liability $ 1,785 $ — $ — $ 1,785
Schedule of derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3)	Year ended December 31, 2019 2018 Balance at beginning of year $ 2,134 $ 2,934 Additions to derivative instruments 243 604 Reclassification on conversion (265 ) (352 ) Loss (gain) on change in fair value of derivative liability (327 ) (1,052 ) Balance at end of year $ 1,785 $ 2,134

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]
Schedule of additional information of cash flow	Year Ended December 31, 2019 2018 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 473 $ 503 Debentures converted to common stock 331 361 Derivative liability extinguished upon conversion of notes payable 265 352 Derivative liability issued 243 604 Accounts payable paid through issuance of debentures — 15

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	December 31, 2019 2018 Accrued compensation and benefits $ 1,326 $ 1,326 Accrued research and development 233 188 Accrued other 307 300 Total accrued expenses $ 1,866 $ 1,814

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of black scholes valuations of derivatives	2019 Volatility 238% - 264 % Expected term (years) 3 - 11 months Risk-free interest rate 1.55% – 1.6 % Dividend yield None

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	Years Ended December 31, 2019 2018 Research and development $ — $ 62 General and administrative — 28 Total stock-based compensation expense $ — $ 90
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate (in thousands) Outstanding at December 31, 2017 14,252 $ 186.25 Granted — $ — Forfeited (1,311 ) $ 474.75 Outstanding at December 31, 2018 12,941 $ 157.00 3.8 $ — Granted — $ — Forfeited (5,255 ) $ 226.90 Outstanding at December 31, 2019 7,686 $ 109.37 2.9 $ — Exercisable at December 31, 2019 7,686 $ 109.37 2.9 $ —

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants [Abstract]
Schedule of transactions involving of warrants	Number of Weighted- Weighted- Aggregate (in thousands) Outstanding at December 31, 2017 121,829 $ 134.75 Granted — $ — Forfeited (21,312 ) $ 396.75 Outstanding at December 31, 2018 100,517 $ 79.00 2.7 $ - Granted — $ — Forfeited (4,187 ) $ 904.91 Outstanding at December 31, 2019 96,330 $ 42.95 1.8 $ - Exercisable at December 31, 2019 96,330 $ 42.95 1.8 $ -
Schedule of outstanding common stock purchase warrants	Number of Weighted- Expiration Issued to consultants 3,758 $ 69.57 January 2020 through August 2023 Issued pursuant to 2015 financings 18,415 $ 210.00 July 2020 through December 2020 Issued pursuant to 2016 financings 58,667 $ 0.01 December 2021 Issued pursuant to 2017 financings 15,490 $ 0.42 March 2022 through April 2022 96,330

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets and liabilities	2019 2018 Deferred tax assets: Net operating loss carryover $ 8,838 $ 8,597 Stock-based compensation 1,920 1,920 Accrued compensation 334 334 Other 30 30 Tax credits 458 458 Total deferred tax assets 11,580 11,339 Less: valuation allowance (11,580 ) (11,339 ) Net deferred tax assets $ — $ —
Schedule of actual tax benefit differs from the expected tax benefit	2019 2018 Statutory federal income tax rate (21.0 )% (21.0 )% State income taxes, net of federal benefits (7.0 )% (7.0 )% Non-deductible items 2.2 % (1,418.0 )% Valuation allowance 25.8 % 1,446.0 % Effective income tax rate — % — %

Management's Plans to Continu_2

Management's Plans to Continue as a Going Concern (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Management's Plans to Continue as a Going Concern (Textual)
Accumulated deficit		$ (60,680)	$ (59,746)
Cash and cash equivalents and restricted cash balances		$ 23
Percentage of total assets		100.00%
Subsequent Event [Member]
Management's Plans to Continue as a Going Concern (Textual)
Amount raised	$ 250

Summary of Critical Accountin_4

Summary of Critical Accounting Policies and Use of Estimates (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shares underlying, outstanding	649,135,510	34,302,796
Shares underlying convertible preferred stock outstanding [Member]
Shares underlying, outstanding	7,911,825	1,055,825
Shares underlying convertible notes outstanding [Member]
Shares underlying, outstanding	641,119,669	33,133,513
Shares underlying warrants outstanding [Member]
Shares underlying, outstanding	96,330	100,517
Shares underlying options outstanding [Member]
Shares underlying, outstanding	7,686	12,941

Summary of Critical Accountin_5

Summary of Critical Accounting Policies and Use of Estimates (Details 1) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Derivative liability	$ 1,785	$ 2,134
Level 1 [Member]
Derivative liability
Level 2 [Member]
Derivative liability
Level 3 [Member]
Derivative liability	$ 1,785

Summary of Critical Accountin_6

Summary of Critical Accounting Policies and Use of Estimates (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Balance at beginning of year	$ 2,134	$ 2,934
Additions to derivative instruments	243	604
Reclassification on conversion	(265)	(352)
Loss (gain) on change in fair value of derivative liability	(327)	(1,052)
Balance at end of year	$ 1,785	$ 2,134

Summary of Critical Accountin_7

Summary of Critical Accounting Policies and Use of Estimates (Details Textual) - USD ($) $ in Thousands	Sep. 17, 2019	Dec. 31, 2019	Dec. 31, 2018
Summary of Critical Accounting Policies and Use of Estimates (Textual)
Research and development		$ 44	$ 208
Cash and restricted cash		20	300
Depreciation expense		$ 2,000	$ 2,000
Reverse stock split	The Company's Board of Directors approved a one-for-twenty five (1-for-25) reverse stock split of the Company's common stock ("Reverse Stock Split").

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Non-cash financing activities:
Common stock issued on conversion of notes payable and derivative liability	$ 473	$ 503
Debentures converted to common stock	331	361
Derivative liability extinguished upon conversion of notes payable	265	352
Derivative liability issued	243	604
Accounts payable paid through issuance of debentures		$ 15

Intellectual Property (Details)

Intellectual Property (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Intellectual Property (Textual)
Payments in cash and common stock	$ 212
Amortization expense	$ 33	$ 17

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Accrued compensation and benefits	$ 1,326	$ 1,326
Accrued research and development	233	188
Accrued other	307	300
Total accrued expenses	$ 1,866	$ 1,814

Derivative Liability (Details)

Derivative Liability (Details)	Dec. 31, 2019
Volatility [Member] | Minimum [Member]
Derivative liability measurement input	238.00%
Volatility [Member] | Maximum [Member]
Derivative liability measurement input	264.00%
Expected term (years) [Member] | Minimum [Member]
Derivative liability term	3 months
Expected term (years) [Member] | Maximum [Member]
Derivative liability term	11 months
Risk-free interest rate [Member] | Minimum [Member]
Derivative liability measurement input	1.55%
Risk-free interest rate [Member] | Maximum [Member]
Derivative liability measurement input	1.60%
Dividend yield [Member]
Derivative liability measurement input

Derivative Liability (Details T

Derivative Liability (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Derivative Liability (Textual)
Gain on change in fair value of the derivative liability	$ 300	$ 1,100
Derivative Liability	$ 1,800	$ 2,100

Capital Stock and Stockholder_2

Capital Stock and Stockholders' Deficit (Details) - USD ($)	Sep. 17, 2019	Jan. 31, 2019	Apr. 30, 2017	Mar. 31, 2017	Apr. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2015
Capital Stock and Stockholders' Deficit (Textual)
Conversion price						$ 0.125
Preferred stock, outstanding
Reverse stock split, description	The Company's Board of Directors approved a one-for-twenty five (1-for-25) reverse stock split of the Company's common stock ("Reverse Stock Split").
Equity financings and conversions of debentures, description						As a result past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $13.25 per share at December 31, 2019, (ii) our Series B Preferred Stock has been reduced to $0.01 per share at December 31, 2019, (iii) 200 shares of our Series C preferred stock has been reduced to $0.50 per share at December 31, 2019, (iv) 90.43418 shares of our Series C Preferred Stock has been reduced to $0.25 per share at December 31, 2019, and (v) our Series D Preferred stock has been reduced to $0.125 per share at December 31, 2019.
Conversion and exercise price resets, description						As a result past equity financings and conversions of debentures, the conversion prices of (i) our Series A Preferred Stock has been reduced to $13.25 per share at December 31, 2019, (ii) 200 shares of our Series C preferred stock has been reduced to $0.50 per share at December 31, 2019, (iii) 90.43418 shares of our Series C Preferred Stock has been reduced to $0.25 per share at December 31, 2019, (iv) our Series D Preferred stock has been reduced to $0.125 per share at December 31, 2019, and (v) our Series B Preferred Stock has been reduced to $0.01 per share at December 31, 2019. The exercise prices of the outstanding warrants issued in conjunction with (i) the Series B Preferred Stock have been reduced to $0.01 per share, (ii) 200 shares of Series C Preferred Stock have been reduced to $0.50 per share, and (iii) 91.43418 shares of Series C preferred Stock have been reduced to $0.25 per share, respectively, as of December 31, 2019.
Deemed dividends						$ 54,000	$ 196,000
Common Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares						15,265,468	2,947,000
Value of number of shares issued						$ 471,583	$ 503,308
Principal amount of senior convertible debentures						$ 331,415	$ 361,255
Series C Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Reduction in conversion price (in dollars per share)						$ 0.25
Number of shares issued upon conversion						200
Preferred stock, outstanding						290	290
Exercise prices						$ 0.25
Series C Preferred Stock [Member] | April 2017 Offering [Member]
Capital Stock and Stockholders' Deficit (Textual)
Number of shares issued upon conversion						361,737
Preferred stock, par value						$ 1,000
Preferred stock, stated value						$ 0.25
Sale of stock, shares			90.43148
Sale of stock value			$ 90,431
Common stock purchase warrants			14,469
Purchase warrants, description						The Investors also received an aggregate of approximately: (i) 4,823 Series M Warrants, (ii) 4,823 Series N Warrants and (iii) 4,823 Series O Warrants. The Series M Warrants have an exercise price of $0.25 per share (as of December 31, 2019), subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants had an exercise price of $18.75 per share upon issuance, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants had an exercise price of $18.75, upon issuance subject to adjustment, and a term of twelve (12) months from the date of issuance.
Series C Preferred Stock [Member] | March 2017 Offering [Member]
Capital Stock and Stockholders' Deficit (Textual)
Shares of preferred stock subject to adjustment				90.43418
Conversion price						$ 0.50
Number of shares issued upon conversion						400,000
Preferred stock, par value						$ 1,000
Preferred stock, stated value						$ 0.25
Sale of stock, shares				200
Sale of stock value				$ 200,000
Common stock purchase warrants				32,001
Purchase warrants, description						The Investors also received an aggregate of approximately: (i) 10,667 Series M common stock purchase warrants ("Series M Warrants"), (ii) 10,667 Series N common stock purchase warrants ("Series N Warrants") and (iii) 10,667 Series O common stock purchase warrants ("Series O Warrants") (collectively, the "Warrants"). The Series M Warrants have an exercise price of $0.50 per share (as of December 31, 2019), subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants had an exercise price of $18.75 per share upon issuance, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants had an exercise price of $18.75 upon issuance, subject to adjustment, and a term of twelve (12) months from the date of issuance.
Series D 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares		5,000					5,000
Value of number of shares issued		$ 5,000
Preferred stock, par value							$ 0.0001
Preferred stock, stated value							$ 1
Series A Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Conversion price						$ 13.25
Preferred stock, outstanding						134	134
Series C 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares					290.43148
Conversion price					$ 18.75
Preferred stock, stated value			$ 1,000		$ 1,000
Subsequent equity sales period					12 months
Series B 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares								1,000
Conversion price								$ 18.75
Preferred stock, stated value								$ 1,000
Series A 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares									1,853
Conversion price									$ 112.50
Preferred stock, stated value									$ 1,000
Beneficial ownership limitation percentage									9.99%
Subsequent equity sales period									18 months
Series B Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Reduction in conversion price (in dollars per share)						$ 0.50
Number of shares issued upon conversion						90.4
Preferred stock, outstanding						71	71
Exercise prices						$ 0.01
Series D Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Preferred stock, outstanding						5,000
Reverse stock split, description						Each share of Series D Preferred Stock held by a Holder, as such, was entitled to 30,001 votes.
Series D Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Deficit (Textual)
Stock issued during period, shares		5,000
Value of number of shares issued		$ 5,000

Stock Options (Details)

Stock Options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Total stock-based compensation expense		$ 90
Research and development [Member]
Total stock-based compensation expense		62
General and administrative [Member]
Total stock-based compensation expense		$ 28

Stock Options (Details 1)

Stock Options (Details 1) - Stock Options [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of shares
Outstanding at beginning	12,941	14,252
Granted
Forfeited	(5,255)	(1,311)
Outstanding at ending	7,686	12,941
Exercisable at ending	7,686
Weighted-average exercise price
Outstanding at beginning	$ 157	$ 186.25
Granted
Forfeited	226.90	474.75
Outstanding at ending	109.37	$ 157
Exercisable at ending	$ 109.37
Weighted-average remaining contractual term (in years)
Outstanding at ending	2 years 10 months 25 days	3 years 9 months 18 days
Exercisable at ending	2 years 10 months 25 days
Aggregate intrinsic value (in thousands)
Outstanding at ending
Exercisable at ending

Stock Options (Details Textual)

Stock Options (Details Textual)	12 Months Ended
	Dec. 31, 2019shares
2007 Executive Compensation Plan [Member]
Maximum annual grants	2,000
Number of shares authorized	8,000
2007 Executive Compensation Plan [Member] | Common Stock [Member]
Number of shares granted	7,228
Number of shares forfited	5,595
Number of shares available for future issuence	6,367
2009 Executive Compensation Plan [Member]
Number of shares authorized	8,000
Number of shares granted	6,595
Number of shares forfited	4,631
Number of shares available for future issuence	6,036
Inducement Award Stock Option Plan [Member]
Number of shares authorized	12,000
Number of shares granted	8,454
2017 Equity Compensation Plan [Member]
Number of shares authorized	80,000
Number of shares available for future issuence	80,000

Warrants (Details)

Warrants (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of shares
Outstanding at beginning	100,517	121,829
Granted
Forfeited	(4,187)	(21,312)
Outstanding at ending	96,330	100,517
Exercisable at ending	96,330
Weighted-average exercise price
Outstanding at beginning	$ 79	$ 134.75
Granted
Forfeited	904.91	396.75
Outstanding at ending	42.95	$ 79
Exercisable at ending	$ 42.95
Outstanding at ending	1 year 9 months 18 days	2 years 8 months 12 days
Exercisable at ending	1 year 9 months 18 days
Outstanding at ending
Exercisable at ending

Warrants (Details 1)

Warrants (Details 1) - Warrant [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of shares	96,330
2015 financings [Member]
Number of shares	18,415
Weighted Average Exercise price | $ / shares	$ 210
Expiration date beginning	2020-07
Expiration date ending	2020-12
2016 financings [Member]
Number of shares	58,667
Weighted Average Exercise price | $ / shares	$ 0.01
Expiration date ending	2021-12
2017 financings [Member]
Number of shares	15,490
Weighted Average Exercise price | $ / shares	$ 0.42
Expiration date beginning	2022-03
Expiration date ending	2022-04
Consultant [Member]
Number of shares	3,758
Weighted Average Exercise price | $ / shares	$ 69.57
Expiration date beginning	2020-01
Expiration date ending	2023-08

Warrants (Details Textual)

Warrants (Details Textual)	Dec. 31, 2019$ / shares
Series B Preferred Stock [Member]
Warrants (Details Textual)
Exercise price of warrants	$ 0.01
Series C Preferred Stock [Member]
Warrants (Details Textual)
Exercise price of warrants	0.25
Series C Preferred Stock [Member] | Minimum [Member]
Warrants (Details Textual)
Exercise price of warrants	0.25
Series C Preferred Stock [Member] | Maximum [Member]
Warrants (Details Textual)
Exercise price of warrants	$ 0.50

Convertible Debentures and no_2

Convertible Debentures and notes (Details) - USD ($) $ in Thousands	Dec. 13, 2018	Jul. 03, 2018	Sep. 12, 2017	Jul. 16, 2019	Jul. 31, 2018	Sep. 30, 2017	Dec. 31, 2019	Dec. 31, 2018
Convertible Debentures (Textual)
Maturity date						Oct. 1, 2020
Description of convertible debentures							The Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions.
Percentage of outstanding debentures							67.00%
Percentage of partial liquidated damages fee for each investor							2.00%
Percentage of securities issued investors							50.10%
Debt issued					96,000
Sstated value of the preferred shares
Investor [Member]
Convertible Debentures (Textual)
Percentage of outstanding debentures							67.00%
Percentage of partial liquidated damages fee for each investor							2.00%
Percentage of securities issued investors							50.10%
Convertible promissory notes [Member]
Convertible Debentures (Textual)
Principal amount	$ 25,000
Proceeds from debt	$ 25,000
Maturity date	Jun. 30, 2019
Bear interest rate	10.00%
Lowest trade price	75.00%
Convertible debentures [Member]
Convertible Debentures (Textual)
Percentage of outstanding debentures							67.00%
Percentage of partial liquidated damages fee for each investor							2.00%
Percentage of securities issued investors							50.10%
Securities purchase agreement [Member]
Convertible Debentures (Textual)
Cash received		$ 500,000
Principal amount		515,000
Principal amount of senior convertible debentures		515,000		$ 154,000
Cancellation amount		$ 15,000
Description of convertible debentures							The Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions.
Mature date description				On July 16, 2019, we entered into securities purchase agreements ("Securities Purchase Agreement") with certain institutional investors (the "Investors"). Pursuant to the Securities Purchase Agreement, we issued an aggregate of $154,000 of senior convertible debentures ("Debentures") in exchange for the extension of the maturity date of our December 2018 convertible notes and certain of our July 2018 and September 2017 convertible debentures, and the waiver of certain default provisions of our July 2018 and September 2017 convertible debentures. We have charged $154,000 to finance cost at the date of issuance.
Finance cost charge						$ 154,000
Exchange Agreemen [Member]
Convertible Debentures (Textual)
Cash received			$ 250,000
Principal amount			320,000
Cancellation amount			$ 70,000
Description of convertible debentures			The Debentures to be issued to the Investors (i) are non-interest bearing, (ii) have a maturity date of September 12, 2018 and (iii) are convertible into shares of common stock ("Common Stock") of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $8.25 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date.
Registration Rights Agreement [Member]
Convertible Debentures (Textual)
Percentage of partial liquidated damages fee for each investor							1.50%
Registration Rights Agreement [Member] | Common Stock [Member]
Convertible Debentures (Textual)
Conversion of stock, percentage							100.00%
Sabby Volatility Warrant Master Fund, Ltd. [Member]
Convertible Debentures (Textual)
Maturity date							Nov. 20, 2020
Debt issued							26,235
Accounts payable							$ 26,235
Series A 0% Convertible Preferred Stock [Member]
Convertible Debentures (Textual)
Preferred shares exchanged			1,614.8125
Sstated value of the preferred shares			$ 1,600
Exchange Agreemen [Member] | Investor [Member]
Convertible Debentures (Textual)
Principal amount of senior convertible debentures			$ 2,500
Series B 0% Convertible Preferred Stock [Member]
Convertible Debentures (Textual)
Preferred shares exchanged			890
Sstated value of the preferred shares			$ 900
Extended Maturity [Member]
Convertible Debentures (Textual)
Maturity date					Mar. 31, 2020	Jul. 16, 2020
Extended Maturity [Member] | Convertible promissory notes [Member]
Convertible Debentures (Textual)
Maturity date	Jul. 16, 2020
Extended Maturity [Member] | Exchange Agreemen [Member]
Convertible Debentures (Textual)
Maturity date			Jul. 16, 2020

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryover	$ 8,838	$ 8,597
Stock-based compensation	1,920	1,920
Accrued compensation	334	334
Other	30	30
Tax credits	458	458
Total deferred tax assets	11,580	11,339
Less: valuation allowance	(11,580)	(11,339)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(7.00%)	(7.00%)
Non-deductible items	2.20%	(1418.00%)
Valuation allowance	25.80%	1446.00%
Effective income tax rate

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income taxes (Textual)
Net operating loss carryforwards	$ 41,200
Net operating loss carryforwards expire amount	$ 39,900
Expiration period	Expire at various dates through 2037.
Research and development tax credits	$ 458	$ 458
Expiration period for tax credit	Expire from 2028 through 2037
Increased in valuation allowance	$ 241	$ 178
Federal income tax rate	21.00%	21.00%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	May 02, 2020	Mar. 31, 2020	Mar. 06, 2020	Dec. 31, 2019
Subsequent Events (Textual)
Subsequent event, description				Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures and notes issued in our December 2018 note offering, July 2018 debenture offering and September 2017 debenture offering (collectively, the "Debenture Offerings") and extended the maturity date of such debentures until July 16, 2020.
Subsequent Event [Member]
Subsequent Events (Textual)
Principal amount		$ 451,662
Aggregate shares of common stock		131,351,247
Convertible debentures [Member]
Subsequent Events (Textual)
Debentures outstanding				67.00%
Convertible debentures [Member] | Subsequent Event [Member]
Subsequent Events (Textual)
Description of convertible debentures			The Debentures issued (i) are non-interest bearing, (ii) have a maturity date of July 16, 2020 and (iii) are convertible into shares of common stock ("Common Stock") of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the holder upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date.
Senior Convertible debentures [Member] | Subsequent Event [Member]
Subsequent Events (Textual)
Principal amount			$ 250
Series E 0% Convertible Preferred Stock [Member] | Forecast [Member]
Subsequent Events (Textual)
Sale of shares	5,000
Per share price	$ 1
Aggregate gross proceeds	$ 5
Series E Preferred Stock Member [Member] | Forecast [Member]
Subsequent Events (Textual)
Subsequent event, description	With respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2022 only, each share of Series E Preferred Stock held by a holder, as such, is entitled to 100,000 votes.
Per share price	$ 1
Conversion price	$ 0.01